Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNA-SARC
2024-517678-12-00Phase 2Completed
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Jan 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of annamycin in soft tissue sarcoma (STS), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoints: Recommended Phase 2 Dose (RP2D) and 3-month progression-free survival (PFS). Started Jan 2025; status: completed.
02
Drugs
annamycin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-517678-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517678-12-00.